<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897309</url>
  </required_header>
  <id_info>
    <org_study_id>VXA-NVV-103</org_study_id>
    <nct_id>NCT03897309</nct_id>
  </id_info>
  <brief_title>Safety &amp; Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines</brief_title>
  <acronym>VXA-NVV-103</acronym>
  <official_title>A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety&#xD;
      and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1&#xD;
      or GII.4 VP1 with Monovalent or Bivalent Dosing in Healthy Adult Volunteers. The study&#xD;
      consists of 2 parts: Part 1 is the double-blinded portion where subjects will be randomized&#xD;
      to one of two monovalent vaccine groups, bivalent vaccine group or placebo. Subjects will be&#xD;
      followed for ~4 weeks post vaccination for safety and immunogenicity. Part 2 will consist of&#xD;
      an open label booster vaccination for the bivalent treatment group ~4 months post initial&#xD;
      vaccination. All subjects will be followed for long term safety for 1 year post initial&#xD;
      vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety&#xD;
      and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1&#xD;
      or GII.4 VP1 with Monovalent or Bivalent Dosing in Healthy Adult Volunteers. The study&#xD;
      consists of 2 parts with will enroll 86 subjects:&#xD;
&#xD;
      Part 1 - Double Blind Period: Post confirmation of eligibility subjects will be randomized in&#xD;
      a double-blinded manner to one of four treatment arms. Treatment Group 1 will contain an&#xD;
      open-label sentinel group of 6 subjects to be enrolled prior to initiation of subsequent&#xD;
      treatment groups. After review of the safety data and confirmation the dose is well tolerated&#xD;
      through Study Day 8, the rest of the study will proceed in a double-blinded, randomized&#xD;
      fashion. The 6 sentinel subjects will not be part of the 16 subjects in Treatment Group 1 to&#xD;
      be enrolled in the double-blinded placebo-controlled cohort; randomization will be 1:1:2:1&#xD;
      for Treatment Groups 1 through 4 respectively.&#xD;
&#xD;
      Study Design and Vaccine Groups&#xD;
&#xD;
        1. Monovalent GII.4 VXA-G2.4-NS (6 sentinels / 16 randomized)&#xD;
&#xD;
        2. Monovalent GI.1 VXA-G1.1-NN (16 randomized)&#xD;
&#xD;
        3. Bivalent GII.4/GI.1 VXA-G2.4-NS + VXA-G1.1-NN (32 randomized)&#xD;
&#xD;
        4. Placebo Tablets no vaccine (16 randomized)&#xD;
&#xD;
      Subjects will be followed for ~4 weeks post vaccination for safety and immunogenicity. The&#xD;
      study database will be locked post completion of Day 29 visits.&#xD;
&#xD;
      Part 2 will consist of an open label booster vaccination for the bivalent treatment group ~4&#xD;
      months post initial vaccination. Subjects will be followed for safety and immunogenicity for&#xD;
      ~4 weeks post the boost.&#xD;
&#xD;
      All subjects will be followed for long term safety for 1 year post initial vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label sentinel followed by Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study subjects, study site and study team will remain blinded to treatment during study period 1 (initial vaccination through Day 29 visits and subsequent database lock)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Solicited Adverse Events</measure>
    <time_frame>Day 1 (Vaccination) to 7 days post vaccination</time_frame>
    <description>Comparison of rate of occurance and severity of Solicited Adverse Events observed between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Unsolicited Adverse Events</measure>
    <time_frame>Day 1 (Vaccination) to 28 days post vaccination</time_frame>
    <description>Comparison of the rate of occurrence and severity of unsolicited Adverse Events observed between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity - VP1 Specific IgA ASC</measure>
    <time_frame>Day 1 (vaccination) to 7 days post-vaccination</time_frame>
    <description>LS Mean difference in VP1 specific IgA ASC between vaccine and placebo group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity - BT50 Assay</measure>
    <time_frame>Day 1 (vaccination) to 28 days post-vaccination</time_frame>
    <description>Difference in HBGA blocking antibodies (by blocking titer fifty assay [BT50]) between vaccine and placebo groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - VP1 specific serum IgG</measure>
    <time_frame>Day 1 (vaccination) to 7 days post-vaccination</time_frame>
    <description>LS Mean difference in VP1 specific serum IgG between vaccine and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Norovirus Infection</condition>
  <arm_group>
    <arm_group_label>Monovalent GI.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monovalent GI.1 tableted vaccine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovalent GII.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monovalent GII.4 tableted vaccine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalent GI.1 and GII.4 vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-G1.1-NN</intervention_name>
    <description>Monovalent GI.1 tableted vaccine</description>
    <arm_group_label>Bivalent GI.1 and GII.4 vaccine group</arm_group_label>
    <arm_group_label>Monovalent GI.1</arm_group_label>
    <other_name>GI.1 oral vaccine tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-G2.4-NS</intervention_name>
    <description>Monovalent GII.4 tableted vaccine</description>
    <arm_group_label>Bivalent GI.1 and GII.4 vaccine group</arm_group_label>
    <arm_group_label>Monovalent GII.4</arm_group_label>
    <other_name>GII.4 oral vaccine tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Tablets matching in number and appearance to active vaccine doses</description>
    <arm_group_label>Monovalent GI.1</arm_group_label>
    <arm_group_label>Monovalent GII.4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Oral tablets for control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the ages of 18 to 49 years, inclusive&#xD;
&#xD;
          -  General good health, without significant medical illness, based on medical history,&#xD;
             physical examination, vital signs, and clinical laboratories&#xD;
&#xD;
          -  Demonstrate comprehension of the protocol procedures and willingness to adhere to all&#xD;
             visits and assessments&#xD;
&#xD;
          -  Body mass index between 17 and 35 at screening&#xD;
&#xD;
          -  Female subjects must have a negative pregnancy test at screening and before each&#xD;
             vaccination and fulfill protocol specified criteria for adequate birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a significant medical condition which in the opinion of the investigator&#xD;
             precludes participation in the study&#xD;
&#xD;
          -  History of cancer or cancer treatment within past 3 years&#xD;
&#xD;
          -  Presence of immunosuppression or medical condition possibly associated with impaired&#xD;
             immune responsiveness, including diabetes mellitus or angioedema&#xD;
&#xD;
          -  Donation or use of blood/blood products within 4 weeks prior to vaccination&#xD;
&#xD;
          -  Diagnosed bleeding disorder or significant bruising or bleeding difficulties that&#xD;
             could make blood draws problematic.&#xD;
&#xD;
          -  Any condition that resulted in the absence or removal of the spleen&#xD;
&#xD;
          -  Positive HIV, HBsAg or HCV tests at the screening visit&#xD;
&#xD;
          -  Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days of&#xD;
             vaccination&#xD;
&#xD;
          -  Use of medications known to affect the immune function within 14 days of vaccination&#xD;
&#xD;
          -  Use of NSAIDs, sulfonylureas, and angiotensin II blockers within 7 days of vaccination&#xD;
&#xD;
          -  Evidence of recent or of current nonbacterial gastroenteritis suggestive of NV&#xD;
             infection to any gastroenteritis within 2 weeks of vaccination&#xD;
&#xD;
          -  History of drug, alcohol or chemical abuse within 1 year of screening or positive&#xD;
             urine drug test at screening&#xD;
&#xD;
          -  Consistent/habitual smoking within 2 months as per medical history&#xD;
&#xD;
          -  History of hypersensitivity or allergic reaction to any component of the&#xD;
             investigational vaccine or placebo&#xD;
&#xD;
          -  Use of any investigational vaccine, drug or device within 8 weeks preceding&#xD;
             vaccination, or planned use of the above stated for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Beth Manning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rapid Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caliciviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study results will be summarized and presented by treatment arm comparisons. Individual subject data will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

